CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 7 enrolled
Drug / intervention
EZN-2279 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01420627
NCT01420627Phase 3Completed
CompareCT.gov

A Study of EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) Administered as a Weekly Intramuscular Injection in Patients With Adenosine Deaminase (ADA)-Deficient Combined Immunodeficiency

Leadiant Biosciences, Inc.·interventional·Posted Aug 19, 2011·Updated Apr 16, 2020

In Brief

A Phase 3 clinical trial evaluating EZN-2279 and Adagen for ADA-SCID and 2 related conditions. Completed, enrolled 7 participants across 6 sites.

Detailed Summary

The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of EZN-2279 in patients with ADA-deficient combined immunodeficiency currently being treated with Adagen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsADA-SCID, Adenosine Deaminase Deficiency, Severe Combined Immunodeficiency
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 19, 2011
Enrollment StartJan 24, 2014
Primary CompletionApr 10, 2018
Study CompletionMay 29, 2019
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 14.9 years ago

Interventions

EZN-2279biological

Weekly administration of EZN-2279 via IM injection

Adagenbiological